Literature DB >> 18931390

Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin.

Hiroshi Ishimoto1, Hiroshi Mukae, Noriho Sakamoto, Misato Amenomori, Takeshi Kitazaki, Yoshifumi Imamura, Hanako Fujita, Hiroshi Ishii, Seiko Nakayama, Katsunori Yanagihara, Shigeru Kohno.   

Abstract

OBJECTIVES: Mucus hypersecretion is a prominent feature in patients with chronic respiratory tract infections such as cystic fibrosis and diffuse panbronchiolitis, and the clinical effectiveness of macrolide antibiotics has been reported in these patients. Because human neutrophil peptide-1 (HNP-1), an antimicrobial peptide in neutrophils, exists in high concentrations in the airway fluid of these patients, we examined the direct effect of HNP-1 on MUC5AC mucin production using NCI-H292 cells. The effects of macrolide antibiotics on the response were also examined.
METHODS: MUC5AC synthesis was assayed using RT-PCR and ELISA. Phosphorylation of ERK1/2 was determined by western blotting.
RESULTS: Stimulation with HNP-1 or lipopolysaccharide (LPS) derived from Pseudomonas aeruginosa increases the production of MUC5AC mRNA and protein, and an additive effect was found upon co-stimulation with both HNP-1 and LPS. Azithromycin and clarithromycin had inhibitory effects on overproduction of MUC5AC induced by HNP-1 or LPS stimulation. Telithromycin also had an inhibitory effect on MUC5AC production induced by LPS, but not on production by HNP-1. Phosphorylation of ERK1/2 was induced by HNP-1 or LPS stimulation, and azithromycin, clarithromycin and telithromycin had inhibitory effects on ERK1/2 phosphorylation induced by LPS, but not by HNP-1.
CONCLUSIONS: These findings suggest that neutrophil-derived defensins as bacterial components contribute to excessive mucus production in patients with respiratory tract infections, and that macrolide and ketolide antibiotics directly inhibit these actions by interfering with intracellular signal transduction. However, the mechanism of telithromycin inhibition of MUC5AC synthesis may differ from the response induced by azithromycin and clarithromycin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18931390     DOI: 10.1093/jac/dkn427

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

2.  Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells.

Authors:  Kentaro Nagaoka; Katsunori Yanagihara; Yosuke Harada; Koichi Yamada; Yohei Migiyama; Yoshitomo Morinaga; Hiroo Hasegawa; Koichi Izumikawa; Hiroshi Kakeya; Masaharu Nishimura; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

Review 3.  Targeting mucus hypersecretion: new therapeutic opportunities for COPD?

Authors:  Clémence Martin; Justine Frija-Masson; Pierre-Régis Burgel
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

Review 4.  CFTR, mucins, and mucus obstruction in cystic fibrosis.

Authors:  Silvia M Kreda; C William Davis; Mary Callaghan Rose
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

5.  JNK activation is responsible for mucus overproduction in smoke inhalation injury.

Authors:  Won-Ii Choi; Olga Syrkina; Kun Young Kwon; Deborah A Quinn; Charles A Hales
Journal:  Respir Res       Date:  2010-12-07

6.  Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan.

Authors:  Keishi Oda; Kazuhiro Yatera; Yoshihisa Fujino; Hiroshi Ishimoto; Hiroyuki Nakao; Tetsuya Hanaka; Takaaki Ogoshi; Takashi Kido; Kiyohide Fushimi; Shinya Matsuda; Hiroshi Mukae
Journal:  BMC Pulm Med       Date:  2016-06-08       Impact factor: 3.317

7.  Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia.

Authors:  Carla Maria P Ribeiro; Harry Hurd; Yichao Wu; Mary E B Martino; Lisa Jones; Brian Brighton; Richard C Boucher; Wanda K O'Neal
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

8.  Azithromycin inhibits mucus hypersecretion from airway epithelial cells.

Authors:  Takeshi Shimizu; Shino Shimizu
Journal:  Mediators Inflamm       Date:  2012-04-23       Impact factor: 4.711

Review 9.  Human defensins and LL-37 in mucosal immunity.

Authors:  Mona Doss; Mitchell R White; Tesfaldet Tecle; Kevan L Hartshorn
Journal:  J Leukoc Biol       Date:  2009-10-06       Impact factor: 4.962

Review 10.  Azithromycin in viral infections.

Authors:  Madeleine E Oliver; Timothy S C Hinks
Journal:  Rev Med Virol       Date:  2020-09-23       Impact factor: 11.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.